​

West Pharmaceutical Services (WST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WST Stock Forecast

West Pharmaceutical Services (WST) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $419.50, with a high of $447.00 and a low of $390.00. This represents a 6.97% increase from the last price of $392.15.

$200 $250 $300 $350 $400 $450 High: $447 Avg: $419.5 Low: $390 Last Closed Price: $392.15

WST Stock Rating

West Pharmaceutical Services stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (82.35%), 2 Hold (11.76%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 2 14 Strong Sell Sell Hold Buy Strong Buy

WST Price Target Upside V Benchmarks

TypeNameUpside
StockWest Pharmaceutical Services6.97%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks6.36%

Price Target Trends

1M3M12M
# Anlaysts1418
Avg Price Target$440.00$420.00$359.00
Last Closing Price$392.15$392.15$392.15
Upside/Downside12.20%7.10%-8.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 264121--17
Sep, 263112--16
Aug, 263112--16
Jul, 262111-115
Jun, 262103--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2026Luke SergottBarclays$440.00$372.6418.08%12.20%
Sep 22, 2026Kallum TitchmarshMorgan Stanley$400.00$361.7310.58%2.00%
Sep 09, 2026UBS$415.00$338.0622.76%5.83%
Jul 27, 2026Evercore ISI$425.00$333.1227.58%8.38%
Jul 13, 2026BNP Paribas$447.00$353.7126.37%13.99%
Jul 09, 2026Morgan Stanley$365.00$353.683.20%-6.92%
Jul 06, 2026Daniel MarkowitzEvercore ISI$410.00$359.2714.12%4.55%
Jul 02, 2026KeyBanc$390.00$365.006.85%-0.55%
Jun 09, 2026Luke SergottBarclays$400.00$319.7525.10%2.00%
Apr 27, 2026Morgan Stanley$315.00$306.392.81%-19.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.BuyBuyhold
Oct 07, 2026BarclaysOverweightOverweighthold
Sep 22, 2026Morgan StanleyBuyOverweightupgrade
Aug 03, 2026CitigroupBuyBuyhold
Jul 27, 2026Evercore ISIOutperformOutperformhold
Jul 15, 2026Cowen & Co.BuyBuyhold
Jul 13, 2026Exane BNP ParibasOutperforminitialise
Jul 06, 2026Evercore ISIOutperformOutperformhold
Jul 02, 2026KeyBancOverweightOverweighthold
Jun 09, 2026BarclaysOverweightupgrade

Financial Forecast

EPS Forecast

$6 $7 $8 $9 $10 $11 $12 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.90$7.88$7.99$6.75$6.83---
Avg Forecast$8.49$8.17$8.01$6.63$7.45$8.77$9.98$11.10
High Forecast$8.62$8.27$8.10$6.67$7.67$9.11$10.17$11.31
Low Forecast$8.40$8.10$7.96$6.55$7.30$8.29$9.82$10.92
Surprise %4.83%-3.55%-0.25%1.81%-8.32%---

Revenue Forecast

$3B $3B $3B $3B $4B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.83B$2.89B$2.95B$2.89B$3.07B---
Avg Forecast$2.81B$2.84B$2.96B$2.88B$3.04B$3.31B$3.50B$3.71B
High Forecast$2.84B$2.86B$3.00B$2.89B$3.06B$3.31B$3.52B$3.77B
Low Forecast$2.79B$2.82B$2.92B$2.85B$3.03B$3.31B$3.48B$3.67B
Surprise %0.70%1.77%-0.22%0.27%1.14%---

Net Income Forecast

$400M $500M $600M $700M $800M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$661.80M$585.90M$593.40M$492.70M$493.70M---
Avg Forecast$503.69M$609.47M$593.40M$499.60M$563.43M$637.89M$749.00M$835.83M
High Forecast$604.43M$731.37M$712.08M$502.29M$577.28M$685.83M$765.83M$851.78M
Low Forecast$402.95M$487.58M$474.72M$493.31M$549.58M$623.92M$739.61M$822.61M
Surprise %31.39%-3.87%--1.38%-12.38%---

WST Forecast FAQ

Is West Pharmaceutical Services stock a buy?

West Pharmaceutical Services stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that West Pharmaceutical Services is a favorable investment for most analysts.

What is West Pharmaceutical Services's price target?

West Pharmaceutical Services's price target, set by 17 Wall Street analysts, averages $419.5 over the next 12 months. The price target range spans from $390 at the low end to $447 at the high end, suggesting a potential 6.97% change from the previous closing price of $392.15.

How does West Pharmaceutical Services stock forecast compare to its benchmarks?

West Pharmaceutical Services's stock forecast shows a 6.97% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical instruments & supplies stocks industry (6.36%).

What is the breakdown of analyst ratings for West Pharmaceutical Services over the past three months?

  • October 2026: 23.53% Strong Buy, 70.59% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is West Pharmaceutical Services’s EPS forecast?

West Pharmaceutical Services's average annual EPS forecast for its fiscal year ending in December 2026 is $8.77, marking a 28.40% increase from the reported $6.83 in 2025. Estimates for the following years are $9.98 in 2027, and $11.1 in 2028.

What is West Pharmaceutical Services’s revenue forecast?

West Pharmaceutical Services's average annual revenue forecast for its fiscal year ending in December 2026 is $3.31B, reflecting a 7.67% increase from the reported $3.07B in 2025. The forecast for 2027 is $3.5B, and $3.71B for 2028.

What is West Pharmaceutical Services’s net income forecast?

West Pharmaceutical Services's net income forecast for the fiscal year ending in December 2026 stands at $637.89M, representing an 29.21% increase from the reported $493.7M in 2025. Projections indicate $749M in 2027, and $835.83M in 2028.